Revance CEO Browne Sheds Light on History, Challenges and Future Following Its Recent Clinical News
Share This Episode
In this podcast, AIS Co-Chair Mark Foley – a successful executive in his own right – asks Dan Browne, CEO of Revance Therapeutics several compelling questions.
How did his love for the outdoors lead to his career in medical technology? What led him to co-found Revance with two friends? What were some of the important “pivot points” in building this exciting aesthetics company? What’s next for Revance following last week’s exciting news about its long-acting neuromodulator DaxibotulinumtoxinA for Injection (RT002).
President & CEO
Dan Browne is a co-founder of Revance and has served as its President and Chief Executive Officer since incubating the company and its first institutional venture financing in 2006 and taking the company public in 2014. Dan has more than 25 years of executive leadership experience across both biopharmaceuticals and medical technologies. Prior to joining Revance, Mr. Browne served as President and Chief Executive Officer of Neomend, Inc., a medical technology and biomaterials company and Prograft Medical Inc., a medical device company focused on minimally-invasive treatments of cardiovascular and vascular disease. Prior to Neomend and Prograft, Dan spent more than 16 years in various leadership positions in innovative product development, sales and marketing and business development in the Gore Medical Products Division of W.L. Gore & Associates, Inc., a global, multi-billion dollar technology company, serving as Business Leader in the Medical Products Division as his final role at the company.